Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a Mucus-Busting supplement boost an IBS drug?

NCT ID NCT06727422

Symptom relief Sponsor: Mark Pimentel, MD Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether adding the supplement N-acetylcysteine (NAC) to the antibiotic rifaximin can better relieve symptoms of irritable bowel syndrome with diarrhea (IBS-D). The idea is that NAC may break down mucus in the gut, helping rifaximin work more effectively. The trial will enroll 225 adults with IBS-D who still have symptoms despite standard care. Participants will receive one of two doses of the combination or a placebo for several weeks, and researchers will track changes in abdominal pain and stool consistency.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
rifaximin and N-acetylcysteine (NAC) combination
What this could lead to
If it works, this could offer a more effective treatment for IBS-D symptoms, reducing abdominal pain and diarrhea better than current options.
What could go wrong
This is an early phase 2b trial with only 225 participants. The combination is not yet approved, and it may not prove more effective than rifaximin alone. Side effects are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 225 people

The number the study aims to enrol. It can still change while the study runs.

Started

Feb 2026

Expected to finish

Jan 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Male or non-pregnant, non-lactating female patients ≥ 18 years of age 2. Diagnosed with IBS confirmed by the Rome IV criteria, with associated symptoms of diarrhea as noted below in 4(b). 3. Do not have adequate relief of IBS symptoms of abdominal pain, stool consistency or stool frequency 4. Have daily IBS symptom scores during screening as below: 1. Weekly average score of worst daily abdominal pain \>3.0 on a 0-10 point scale 2. At least one stool with a consistency of Type 6 or 7 on the Bristol Exclusion Criteria: 1. Present with the following symptoms of IBS with constipation: 1. Less than 3 bowel movements a week, 2. Hard or lumpy stools, and 3. Excessive straining during a bowel movement. 2. History of inflammatory bowel disease, celiac disease, GI surgery (except cholecystectomy and/or appendectomy) 3. Evidence of active duodenal ulcer, gastric ulcer, diverticulitis, or active infectious gastroenteritis 4. Current diagnosis of asthma 5. Current user of NAC and/or rifaximin 6. Systemic antibiotic use in the last month 7. Not currently on a prokinetic drug 8. A significant medical condition including but not limited to hepatic, uncontrolled diabetes, renal, cardiovascular, pulmonary, uncontrolled thyroid disease. or psychiatric disease, which in the opinion of investigator precludes study participation

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for IBS - irritable bowel syndrome are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

irritable bowel syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

IBS - irritable bowel syndrome IBS-D (diarrhea-predominant)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Cedars-Sinai Medical Center

    RECRUITING

    Los Angeles, California, 90048, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.